DOCSLIB.ORG

Specialty Pharmacy Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Specialty Pharmacy Drug List SPECIALTY PHARMACY DRUG LIST Specialty medications are used to treat complex conditions like multiple sclerosis, hepatitis C and rheumatoid arthritis. The following is a list of specialty medications. Those medications marked with an asterisk must be obtained through Cigna Home Delivery Pharmacy for it to be covered. This only applies when the medication is covered under the pharmacy benefit and when your plan requires the use of Cigna Home Delivery Pharmacy for specialty medications. Please note, this list is subject to change. Drug Name A Alimta Atripla Bleo 15K Cholbam abacavir Alkeran Aubagio* bleomycin chorionic abacavir-lamivudine- Aloxi Avastin Blincyto gonadotropin zidovudine Alphanate* Avonex* Boniva* cidofovir Abraxane Alphanine SD* azacitidine Bosulif* Cimzia* Actemra* Alprolix* Azasan* Botox Cinqair Acthrel Amicar* azathioprine* Bravelle Cinryze amifostine Busulfex cisplatin Actimmune* B Adagen aminocaproic acid* cladribine Baraclude* C Adcetris Ampyra* Clolar BCG Vaccine (Tice Cabometyx Adcirca* Amvisc Coagadex Strain) Calcium Folinate adefovir dipivoxil* Amvisc Plus Combivir Bebulin* Campath Adempas Anagrelide* Cometriq Beleodaq Camptosar Adriamycin Anzemet Complera Bendeka* capecitabine* Adrucil Apokyn* Copaxone* Benefix* Caprelsa Advate* Aptivus Copegus* Benlysta carboplatin Adynovate* Aralast NP Corifact Berinert Carimune NF* Afinitor* Aranesp Cosentyx* Betaseron* Casodex* Afinitor Disperz Arcalyst Cosmegen Bethkis* Cayston Afstyla argatroban Cotellic* bexarotene* Cellcept Agrylin* Arixtra Crixivan Bexxar Ceprotin* Akynzeo Arranon cyclophosphamide* Bicalutamide* Cerdelga* Aldurazyme* Arzerra cyclosporine BICNU Cerezyme* Alecensa* Astagraf XL* cyclosporine (oral)* Bivigam* cetrotide Alferon N* Atgam Cyklokapron Offered by: Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, or their affiliates. 874932 j 08/16 © 2016 Cigna. Drug Name Cyramza Erbitux Glassia Invirase Lupaneta Pack* Cystadane* Erivedge* Glatopa* Iprivask* Lupron Depot* Cystagon Erwinaze Gleevec* Iressa Lupron Depot-Ped* cytarabine Esbriet* Gliadel irinotecan Lynparza Cytogam etopophos Gonal-F Isentress Lysteda Cytovene etoposide Granix Istodax Euflexxa* Ixempra M D Evomela Ixinity* Macugen dacarbazine Evotaz Marqibo H Dacogen Exjade* J Matulane Daklinza* Extavia* H.P. Acthar* Jadenu* Mekinist* Darzalex* Eylea Halaven Jakafi melphalan daunorubicin Harvoni* Jetrea Menopur Daunoxome F Hecoria* Jevtana* mesna DDAVP Fabrazyme* Helixate FS* Juxtapid Mesnex decitabine Farydak Hemofil M* methotrexate (oral)* Defitelio* Faslodex Hepagam B K methotrexate (vial) Depocyt Feiba NF* Hepsera* Kadcyla MICRhoGAM Descovy Firazyr* Herceptin Kalbitor Mircera desmopressin Firmagon Hexalen* Kaletra Mirena didanosine Flebogamma DIF* Hizentra* Kalydeco mitomycin Docefrez* Flolan Humate-P* Kanuma mitoxantrone docetaxel* floxuridine Humatrope* Kcentra Moderiba* Doxil fludarabine Humira* Kepivance Monoclate-P* doxorubicin fluorouracil Hyalgan* Keytruda Mononine* Duopa flutamide* Hycamtin* Keytruda Monovisc* Dysport* Follistim AQ Hylenex* Kineret* Mozobil Folotyn Hymovis* Kitabis Pak Mustargen E fondaparinux Hyperhep B S/D Koate-DVI* Myalept Edurant Forteo* Hyperrab S/D Kogenate FS* mycophenolate* Egrifta* Fragmin Hyperrho S/D Kovaltry* mycophenolic acid* Elaprase Fusilev Hyqvia Krystexxa Myfortic* Elelyso* Fuzeon Kuvan* Myobloc I Eligard* Kynamro Myozyme Elitek G ibandronate* Kyprolis* Ellence Gamastan S-D* Ibrance* N Eloctate* Gammagard* Iclusig L Nabi-HB Eloxatin Gammagard S-D* Idamycin PFS lamivudine Naglazyme Elspar Gammaked* idarubicin lamivudine HBV Natpara Emcyt* Gammaplex Idelvion* lamivudine- Natrecor Emend Gamunex-C* Ifex zidovudine Navelbine Empliciti* ganciclovir sodium ifosfamide Lemtrada* Neoral* Emtriva ganirelix acetate ifosfamide-Mesna Lenvima Neulasta Enbrel* Gattex Ilaris* Letairis* Neulasta Onpro* enoxaparin Gazyva Iluvien leucovorin (oral)* Neumega entecavir* Gel-One* imatinib* leucovorin (vial) Neupogen Entyvio* Gelsyn-3* Imbruvica Leukine nevirapine Envarsus XR* gemcitabine Imlygic leuprolide* nevirapine ER Epclusa Gemzar Imogam Rabies-HT levoleucovorin Nexavar* epirubicin Gengraf* Imuran* Lexiva Nexavir Epivir Genotropin* Incivek* Liletta Ninlaro Epivir HBV Genvisc 850* Increlex Lipodox Nipent Epogen Genvoya Infergen* Lonsurf Norditropin Flexpro* epoprostenol Gilenya* Inlyta* Lovenox Norditropin Epzicom Gilotrif Intelence Lucentis Nordiflex* Intron A* Lumizyme 2 Drug Name Northera Privigen* Signifor LAR Tivicay Vivitrol* Norvir Procrit sildenafil* Tobi* Vonvendi Novarel Procysbi Simponi* Tobi Podhaler* Voraxaze Novoeight* Profilnine* Simponi Aria* tobramycin* Votrient* Novoseven RT* Prograf (inj) Simulect Toposar VPRIV* Nplate Prograf (oral)* sirolimus* topotecan* Nucala* Prolastin C Skyla Torisel W Nulojix Proleukin Soliris Tracleer* Wilate* Nuplazid Prolia Somatuline Depot tranexamic acid WinRho SDF* Nutropin AQ* Promacta* Somavert Treanda X Nuwiq Provenge Sovaldi* Trelstar* Provisc Sprycel* Tretten Xalkori* O Pulmozyme* stavudine Trexall* Xeljanz* Obizur Purixan Stelara* Trisenox Xeljanz XR* Ocaliva Stimate Triumeq Xeloda* Octagam* R Stivarga* Trizivir Xenazine octreotide* Rapamune* Strensiq Truvada Xeomin* Odefsey Rasuvo Stribild Tybost Xgeva Odomzo* Rebetol* Sucraid Tykerb* Xiaflex* Ofev Rebif* Supartz* Tysabri* Xolair* Olysio* Rebif Rebidose* Supartz FX* Tyvaso Xtandi* Omnitrope* Reclast* Supprelin LA* Tyzeka* Xuriden Oncaspar Recombinate* Sustiva Xyntha* Onivyde Remicade* Sutent* U Xyrem Opdivo Remodulin Sylatron* Unituxin Y Opsumit* Repatha* Sylvant Uptravi Orencia (IV) Repronex Synagis* Yervoy V Orencia (SQ)* Rescriptor Synarel* Yondelis* Orenitram ER Retrovir Valchlor Synribo Z Orfadin Revatio* Synvisc* Valstar Orkambi Revlimid* Synvisc-One* Vantas* Zaltrap Orthovisc* Reyataz Varubi Zanosar Otezla* Rheumatrex T Vectibix Zarxio Otrexup RhoGam tacrolimus* Velcade Zavesca Ovidrel Rhophylac Tafinlar* Veletri Zelboraf* oxaliplatin Riastap Tagrisso Venclexta Zemaira Ribasphere* Taltz* Ventavis Zemplar (inj) P Ribatab* Tarceva* Victrelis* Zemplar (oral)* paclitaxel ribavirin* Targretin* Vidaza Zepatier* pamidronate* Rilutek* Tasigna* Videx Zerit Panretin* riluzole* Taxotere* Videx EC Zevalin paricalcitol (vial) Rituxan Tecentriq* Viekira Pak* Ziagen paricalcitol (oral)* Rixubis* Tecfidera* Vimizim zidovudine Pegasys* Ruconest Technivie* vinblastine Zinbryta Pegintron* Temodar (inj) Vincasar PFS Zoladex* Perjeta S Temodar (oral)* vincristine zoledronic acid* Photofrin Sabril temozolomide* vinorelbine Zolinza Plegridy* Saizen* teniposide Viracept Zomacton* Pomalyst* Sandimmune tetrabenazine Viramune Zometa* Portrazza Sandimmune (oral)* Tev-Tropin* Viramune XR Zorbtive Praluent* Sandostatin* Thalomid* Virazole* Zortress* Praxbind Sandostatin LAR* Theracys Viread Zydelig Pregnyl Selzentry thiotepa Vistide Zykadia Prezcobix Sensipar Thrombate III Vistogard Zytiga* Prezista Serostim* Thymoglobulin Visudyne Prialt Signifor Thyrogen Vitekta 3 Cigna reserves the right to make changes to the Drug List without notice. Your plan may cover additional medications; please refer to your enrollment materials for details. Cigna does not take responsibility for any medication decisions made by the doctor or pharmacist. Cigna may receive payments from manufacturers of certain preferred brand medications, and in limited instances, certain non-preferred brand medications, that may or may not be shared with your plan depending on its arrangement with Cigna. Depending upon plan design, market conditions, the extent to which manufacturer payments are shared with your plan and other factors as of the date of service, the preferred brand medication may or may not represent the lowest-cost brand medication within its class for you and/or your plan. Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and medically necessary. If your plan provides coverage for certain prescription drugs with no cost-share, you may be required to use an in-network pharmacy to fill the prescription. If you use a pharmacy that does not participate in your plan’s network, your prescription may not be covered, or reimbursement may be limited by your plan’s copayment, coinsurance or deductible requirements. Refer to your plan documents for costs and complete details of your plan’s prescription drug coverage. All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company (CHLIC), Connecticut General Life Insurance Company (CGLIC), Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., and HMO or service company subsidiaries of Cigna Health Corporation, including Cigna HealthCare of Arizona, Inc., Cigna HealthCare of California, Inc., Cigna HealthCare of Colorado, Inc., Cigna HealthCare of Connecticut, Inc., Cigna HealthCare of Florida, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of Illinois, Inc., Cigna HealthCare of Indiana, Inc., Cigna HealthCare of St. Louis, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of New Jersey, Inc., Cigna HealthCare of South Carolina, Inc., Cigna HealthCare of Tennessee, Inc. (CHC-TN), and Cigna HealthCare of Texas, Inc. “Cigna Specialty Pharmacy Services” refers to the specialty drug division of Tel-Drug, Inc. and Tel-Drug of Pennsylvania, L.L.C., doing business as Cigna Home Delivery Pharmacy. Policy forms: OK - HP-APP-1 et al (CHLIC), GM6000 C1 et al (CGLIC); TN - HP-POL43/HC-CER1V1 et al (CHLIC), GSA-COVER, et al (CHC-TN). The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. 874932 j 08/16 © 2016 Cigna. Some content provided under license..
Load more

Recommended publications
  • Photoaging & Skin Damage
    Use_for_Revised_OFC_Only_2006_PhotoagingSkinDamage 5/21/13 9:11 AM Page 2 PEORIA (309) 674-7546 MORTON (309) 263-7546 GALESBURG (309) 344-5777 PERU (815) 224-7400 NORMAL (309) 268-9980 CLINTON, IA (563) 242-3571 DAVENPORT, IA (563) 344-7546 SoderstromSkinInstitute.comsoderstromskininstitute.com FROMFrom YOUR Your DERMATOLOGISTDermatologist [email protected]@skinnews.com PHOTOAGING & SKIN DAMAGE Before You Worship The Sun Who’s At Risk? Today, many researchers and dermatologists Skin types that burn easily and tan rarely are believe that wrinkling and aging changes of the skin much more susceptible to the ravages of the sun on the are much more related to sun damage than to age! skin than are those that tan easily, rather than burn. Many of the signs of skin damage from the sun are Light complected, blue-eyed, red-haired people such as pictured on these pages. The decrease in the ozone Swedish, Irish, and English, are usually more suscep- layer, increasing the sun’s intensity, and the increasing tible to photo damage, and their skin shows the signs sun exposure among our population – through work, of photo damage earlier in life and in a more pro- sports, sunbathing and tanning parlors – have taken a nounced manner. Dark complexions give more protec- tremendous toll on our skin. Sun damage to the skin tion from light and the sun. ranks with other serious health dangers of smoking, alcohol, and increased cholesterol, and is being seen in younger and younger people. NO TAN IS A SAFE TAN! Table of Contents Sun Damage .............................................Pg. 1 Skin Cancer..........................................Pgs. 2-3 Mohs Micrographic Surgery ......................Pg.
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Late Stent Thrombosis After Paclitaxel-Eluting Stent Placement in a Patient with Essential Thrombocytosis
    558 Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol 2010;38(8):558-560 Late stent thrombosis after paclitaxel-eluting stent placement in a patient with essential thrombocytosis Esansiyel trombositozlu bir hastada paklitaksel salınımlı stent yerleştirme sonrası gelişen geç stent trombozu Telat Keleş, M.D., Nihal Akar Bayram, M.D., Tahir Durmaz, M.D., Engin Bozkurt, M.D. Department of Cardiology, Ankara Atatürk Education and Research Hospital, Ankara We report on a case of late stent thrombosis after drug- Bu yazıda, esansiyel trombositozlu bir hastada ilaç sa- eluting stent placement in a patient with essential throm- lınımlı stent yerleştirme sonrası gelişen geç stent trom- bocytosis. A 51-year-old male patient with a three-month bozu sunuldu. Üç ay önce sol ön inen artere paklitak- history of paclitaxel-eluting stent placement to the left sel salınımlı stent yerleştirilen 51 yaşındaki erkek hasta anterior descending artery presented with a complaint şiddetli retrosternal göğüs ağrısı yakınmasıyla başvur- of severe retrosternal chest pain. A high platelet count du. İki ay öncesinde hastanın trombosit sayımı yüksek (1,063,000/mm3) was detected two months prior to (1063000/mm3) bulunmuş ve durumu esansiyel trombo- presentation, which was interpreted as essential throm- sitoz olarak yorumlanmıştı. Hasta standart ikili antitrom- bocytosis. He was on standard dual antiplatelet therapy bosit tedavi (aspirin ve klopidogrel) görmekteydi. Elekt- (aspirin and clopidogrel). The electrocardiogram showed rokardiyografide V1-V6 derivasyonlarında ST-segment ST-segment elevation in leads V1-V6. Emergent coro- yükselmesi izlendi. Acil koroner anjiyografide paklitaksel nary angiography revealed thrombotic total occlusion salınımlı stent yerinde trombotik tam tıkanıklık gözlendi. at the location of the paclitaxel-eluting stent.
    [Show full text]
  • May 2020 for Health Professionals Who Care for Cancer Patients
    Systemic Therapy Update Volume 23 Issue 5 May 2020 For Health Professionals Who Care for Cancer Patients Inside This Issue: Editor’s Choice Benefit Drug List New Programs: Neoadjuvant Carboplatin for Triple-Negative New: BRLACTWAC, UGUPAPA, Pegaspargase (LKNOS, Breast Cancer (BRLACTWAC) | Apalutamide for Non- LYNOS), Bevacizumab (Pediatric), IGEV (Pediatric) | Metastatic Castration-Resistant Prostate Cancer (UGUPAPA) Deleted: GIGAVEOCAP, GIGAVEOF, SMAJIFN Drug Update NEW Protocols, PPPOs and Patient Handouts Pharmacare Update – Anticoagulants | Patient Assistance BR: BRLACTWAC | GU: UGUPAPA Programs REVISED Protocols, PPPOs and Patient Handouts Drug Shortages BR: BRAJAC, BRAJACT, BRAJACTG, BRAJACTT, BRAJACTTG, New: Alemtuzumab, Anagrelide | Updated: Hydroxyurea BRAJACTW, BRAJDAC, BRAJFEC, BRAJFECD, BRAJFECDT, Cancer Drug Manual© BRAVAC, BRLAACD, BRLAACDT, BRLATACG, BRLATWAC | New: Abemaciclib, Lurbinectedin | Revised: Apalutamide, GI: GIPGEMABR | GU: UGUPABI, UGUPENZ | LK: ULKBLIN, Durvalumab, Panitumumab, Pembrolizumab ULKMDSA | SA: SAIME | SC: SCDRUGRX | SM: USMAVDAB, ST Update Editorial Board USMAVDT, USMAVTRA, USMAVVC, USMAVVEM Membership Update Resources and Contact Information Editor’s Choice New Programs Effective 01 May 2020, the BC Cancer Provincial Systemic Therapy Program has approved the following new treatment programs. The full details of these programs can be found on the BC Cancer website in the Chemotherapy Protocols section. Breast Neoadjuvant Carboplatin for Locally Advanced, Triple-Negative Breast Cancer (BRLACTWAC) — The Provincial Systemic Therapy Program has approved the addition of carboplatin to the standard taxane- anthracycline neoadjuvant chemotherapy regimens, for patients with stage II and higher triple-negative breast cancer. This regimen consists of carboplatin (given every 3 weeks) in combination with weekly paclitaxel, followed by doxorubicin-cyclophosphamide (AC given every 2 or 3 weeks). Filgrastim support is available for the dose-dense AC option.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Resistance to Antifolates
    Oncogene (2003) 22, 7431–7457 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc Resistance to antifolates Rongbao Zhao1 and I David Goldman*,1 1Departments of Medicine and Molecular, Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA The antifolates were the first class of antimetabolites to the kinetics of the interaction between MTX and DHFR enter the clinics more than 50 years ago. Over the was fully understood, and not until the late 1970s and following decades, a full understanding of their mechan- early 1980s when polyglutamate derivatives of MTX were isms of action and chemotherapeutic potential evolved detected and their pharmacologic importance clarified. along with the mechanisms by which cells develop Likewise, an understanding of tumor cell resistance to resistance to these drugs. These principals served as a antifolates evolved slowly, often paralleling the emergence basis for the subsequent exploration and understanding of of new molecular concepts. As the mechanisms of the mechanisms of resistance to a variety of diverse resistance to antifolates were characterized, this provided antineoplastics with different cellular targets. This section insights and principles that were broadly applicable to describes the bases for intrinsic and acquired antifolate other antineoplastics. Ultimately, this knowledge led to the resistance within the context of the current understanding development of a new generation of antifolates, in the late of the mechanisms of actions and cytotoxic determinants 1980s and 1990s, which are potent direct inhibitors of of these agents. This encompasses impaired drug transport tetrahydrofolate (THF)-cofactor-dependent enzymes. Sev- into cells, augmented drug export, impaired activation of eral of these drugs are now in clinical trials, and the antifolates through polyglutamylation, augmented hydro- activity of one, pemetrexed, has been confirmed in a large lysis of antifolate polyglutamates, increased expression Phase III trial (Vogelzang et al., 2003).
    [Show full text]
  • Xagrid, INN-Anagrelide
    SCIENTIFIC DISCUSSION 1. Introduction Anagrelide hydrochloride monohydrate is a novel imidazoquinazoline originally developed as an inhibitor of platelet aggregation but subsequently found to have value as a platelet-lowering agent for the treatment of patients suffering from Essential thrombocythaemia (ET). ET is one of a number of chronic myeloproliferative disorders characterised by an elevated platelet count due to an autonomous clonal proliferation of bone marrow megakaryocytes. The underlying cause of this proliferation is unknown. Platelet function is generally normal and the cells are able to undergo aggregation and to participate in the haemostatic process in a more or less normal manner. The diagnosis is one of exclusion of reactive causes and other myeloproliferative disorders (MPDs) according to internationally agreed criteria of the Polycythaemia Vera Study Group (PVSG). The main criterion is a sustained platelet level of >600 x 109/L for more than two months. It is estimated that the prevalence of ET in the European Union (EU) is 2-3 per 10,000 persons. ET is a condition that may affect anyone at any stage of life from childhood although the median age of presentation is 60 years. Literature and clinical experience indicate a preponderance of female patients between the ages of 25 and 50 years. Up to two thirds of patients with ET are asymptomatic and a significant number of patients are now being diagnosed as an incidental consequence of the analysis of full blood counts for other health reasons. Generally, the older patient is more likely to be symptomatic at presentation, although younger patients may present with major complications.
    [Show full text]
  • ER Guide to Bleeding Disorders
    Bleeding disorders ER guide to bleeding disorders 1 Table of contents 4 General Guidelines 4–5 national Hemophilia Foundation guidelines 5–10 Treatment options 10 HemopHilia a Name:__________________________________________________________________________________________________ 10–11 national Hemophilia Foundation guidelines Address:________________________________________________________________________________________________ 12 dosage chart Phone:__________________________________________________________________________________________________ 14–15 Treatment products 16 HemopHilia B In case of emergency, contact: ______________________________________________________________________________ 16 national Hemophilia Foundation guidelines Relation to patient:________________________________________________________________________________________ 17 dosage chart 18 Treatment products 19 HemopHilia a or B with inHiBiTors Diagnosis: Hemophilia A: Mild Moderate Severe 20 national Hemophilia Foundation guidelines Inhibitors Inhibitors Bethesda units (if known) ____________________________________ 21 Treatment products Hemophilia B: Mild Moderate Severe 22–23 Von willeBrand disease Inhibitors Inhibitors Bethesda units (if known) ____________________________________ 23–24 national Hemophilia Foundation guidelines von Willebrand disease: Type 1 Type 2 Type 3 Platelet type 25 Treatment products 27 Bibliography Preferred product:_________________________________________________________________________________________ Dose for life-threatening
    [Show full text]
  • Hydroxyurea Induced Oscillations in Twelve Patients with Polycythemia
    Letters to the Editor JAK2 haplotype is a major risk factor for the development of revealed oscillatory behavior with a typical period length myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-9. of 27-30 days. During the presence of oscillations (25.5 6. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibil- years) no bleeding or thromboembolic episodes were ity to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450- observed. 4. Polycythemia vera is a chronic acquired stem cell disor- 7. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally der which affects primarily red blood cells and in many A, Ebert BL, et al. A germline JAK2 SNP is associated with pre- patients also granulocyte and platelet counts. Poly - disposition to the development of JAK2V617F-positive myelo- cythemia vera is associated with an increased risk of proliferative neoplasms. Nat Genet. 2009;41(4):455-9. 1 8. Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D, et al. thromboembolic and hemorrhagic complications. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 Phlebotomy is the therapy of choice.2 In refractory exon 12 mutation-positive polycythemia vera. Leukemia. patients cytoreductive treatment with drugs such as 2009;23(10):1924-6. hydroxyurea is advocated. Hydroxyurea primarily inter- 9. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea Compared with Anagrelide in feres with DNA synthesis by inhibiting ribonucleotide 3 High-Risk Essential Thrombocythemia. N Engl J Med. 2005; reductase in hematopoietic stem cells.
    [Show full text]
  • Cladribine Injection
    PRODUCT MONOGRAPH PrCLADRIBINE INJECTION Solution for Intravenous Injection 1 mg/mL USP Antineoplastic / Chemotherapeutic Agent Fresenius Kabi Canada Ltd. Date of Revision: 165 Galaxy Blvd, Suite 100 June 9, 2015 Toronto, ON M9W 0C8 Control No.: 181078 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 3 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 7 DRUG INTERACTIONS ......................................................................................................... 10 DOSAGE AND ADMINISTRATION ..................................................................................... 11 OVERDOSAGE ....................................................................................................................... 13 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 14 STORAGE AND STABILITY ................................................................................................
    [Show full text]
  • Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
    Molecular Pharmacology Fast Forward. Published on February 19, 2019 as DOI: 10.1124/mol.118.114314 This article has not been copyedited and formatted. The final version may differ from this version. MOL # 114314 Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology Rachael R. Schulte and Richard H. Ho Department of Pediatrics, Division of Pediatric Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN (R.R.S., R.H.H.) Downloaded from molpharm.aspetjournals.org at ASPET Journals on September 28, 2021 1 Molecular Pharmacology Fast Forward. Published on February 19, 2019 as DOI: 10.1124/mol.118.114314 This article has not been copyedited and formatted. The final version may differ from this version. MOL # 114314 OATPs and Cancer Pharmacology Corresponding Author: Richard H. Ho, MD MSCI 397 PRB 2220 Pierce Avenue Vanderbilt University Medical Center Nashville, Tennessee 37232 Downloaded from Tel: (615) 936-2802 Fax: (615) 875-1478 Email: [email protected] molpharm.aspetjournals.org Number of pages of text: 24 Number of tables: 3 Number of figures: 1 References: 204 at ASPET Journals on September 28, 2021 Number of words: Abstract: 201 Introduction: 1386 Discussion: 7737 ABBREVIATIONS: ASBT, apical sodium dependent bile acid transporter; AUC, area under the plasma time:concentration curve; BCRP, breast cancer related protein; BSP, bromosulfophthalein; CCK-8, cholecystokinin octapeptide; DHEAS, dehydroepiandrosterone sulfate; DPDPE, [D-penicillamine2,5] enkephalin; E2G, estradiol-17ß-glucuronide; E3S, estrone-3-sulfate; ENT, equilibrative nucleoside transporter; GCA, glycocholate; HEK, human embryonic kidney; IVS, intervening sequence (notation for intronic mutations); LD, linkage disequilibrium; MATE, multidrug and toxic compound extrusion; MCT, monocarboxylate 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]